These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 17632224)

  • 21. [Which factors modify drug-compliance?].
    Albus M; Burkes S; Scherer J
    Psychiatr Prax; 1995 Nov; 22(6):228-30. PubMed ID: 8570752
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nonadherence to antipsychotic treatment in patients with schizophrenic disorders.
    Svestka J; Bitter I
    Neuro Endocrinol Lett; 2007 Feb; 28 Suppl 1():95-116. PubMed ID: 17262005
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An excitement subscale of the Positive and Negative Syndrome Scale.
    Lindenmayer JP; Brown E; Baker RW; Schuh LM; Shao L; Tohen M; Ahmed S; Stauffer VL
    Schizophr Res; 2004 Jun; 68(2-3):331-7. PubMed ID: 15099614
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Olanzapine monotherapy for late-onset vocal tics in a schizophrenic patient.
    Cheng WJ; Liu HC; Huang MC
    Psychiatry Clin Neurosci; 2007 Dec; 61(6):700-1. PubMed ID: 18081638
    [No Abstract]   [Full Text] [Related]  

  • 25. Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs.
    Liu-Seifert H; Adams DH; Kinon BJ
    BMC Med; 2005 Dec; 3():21. PubMed ID: 16375765
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The case for long-acting antipsychotic agents in the post-CATIE era.
    Nasrallah HA
    Acta Psychiatr Scand; 2007 Apr; 115(4):260-7. PubMed ID: 17355516
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A dilemma born of progress: switching from clozapine to a newer antipsychotic.
    Rafal S; Tsuang MT; Carpenter WT
    Am J Psychiatry; 1999 Jul; 156(7):1086-90. PubMed ID: 10401457
    [No Abstract]   [Full Text] [Related]  

  • 28. Symptoms in neuroleptic-naive, first-episode schizophrenia: response to risperidone.
    Kopala LC; Fredrikson D; Good KP; Honer WG
    Biol Psychiatry; 1996 Feb; 39(4):296-8. PubMed ID: 8645777
    [No Abstract]   [Full Text] [Related]  

  • 29. Attitudes toward antipsychotic medication: the impact of clinical variables and relationships with health professionals.
    Day JC; Bentall RP; Roberts C; Randall F; Rogers A; Cattell D; Healy D; Rae P; Power C
    Arch Gen Psychiatry; 2005 Jul; 62(7):717-24. PubMed ID: 15997012
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia.
    Ascher-Svanum H; Stensland M; Zhao Z; Kinon BJ
    BMC Psychiatry; 2005 Jan; 5():3. PubMed ID: 15649317
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Compliance in the treatment of schizophrenia--project ADHES (the renewed results)].
    Chadzyńska M; Meder J; Tyszkowska M
    Psychiatr Pol; 2008; 42(4):561-70. PubMed ID: 19189600
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Rehospitalization rates of newly diagnosed schizophrenic patients on atypical neuroleptic medication].
    Strasser O; Schmauss M; Messer T
    Psychiatr Prax; 2004 Nov; 31 Suppl 1():S38-40. PubMed ID: 15570496
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of the factors interfering with drug treatment compliance among Brazilian patients with schizophrenia.
    Rosa MA; Marcolin MA; Elkis H
    Braz J Psychiatry; 2005 Sep; 27(3):178-84. PubMed ID: 16224604
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clozapine treatment of dimenhydrinate abuse.
    Prost E; Millson RC
    Am J Psychiatry; 2004 Aug; 161(8):1500. PubMed ID: 15285985
    [No Abstract]   [Full Text] [Related]  

  • 35. Overview of partial compliance.
    Marder SR
    J Clin Psychiatry; 2003; 64 Suppl 16():3-9. PubMed ID: 14680412
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination alprazolam-neuroleptic treatment of the positive and negative symptoms of schizophrenia.
    Wolkowitz OM; Pickar D; Doran AR; Breier A; Tarell J; Paul SM
    Am J Psychiatry; 1986 Jan; 143(1):85-7. PubMed ID: 2867690
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Medication nonadherence may lead to hospitalization.
    J Psychosoc Nurs Ment Health Serv; 2003 Aug; 41(8):10. PubMed ID: 13677006
    [No Abstract]   [Full Text] [Related]  

  • 38. Methodological concerns in a trial of ziprasidone and olanzapine.
    Carnahan RM; Perry PJ
    Am J Psychiatry; 2005 Jul; 162(7):1391; author reply 1391-2. PubMed ID: 15994736
    [No Abstract]   [Full Text] [Related]  

  • 39. Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol.
    Keefe RS; Seidman LJ; Christensen BK; Hamer RM; Sharma T; Sitskoorn MM; Lewine RR; Yurgelun-Todd DA; Gur RC; Tohen M; Tollefson GD; Sanger TM; Lieberman JA
    Am J Psychiatry; 2004 Jun; 161(6):985-95. PubMed ID: 15169686
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cognition, functioning and quality of life in schizophrenia treatment: results of a one-year randomized controlled trial of olanzapine and quetiapine.
    Voruganti LP; Awad AG; Parker G; Forrest C; Usmani Y; Fernando ML; Senthilal S
    Schizophr Res; 2007 Nov; 96(1-3):146-55. PubMed ID: 17728106
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.